Gastrointestinal spread of oral prolonged‐release mesalazine microgranules (Pentasa) dosed as either tablets or sachet

: There is increasing interest in using higher dosages of mesalazine for the treatment of inflammatory bowel disease; however, with current mesalazine products this involves the use of 8–16 tablets per day.

[1]  I. Wilding,et al.  Gamma scintigraphy : an in vivo technique for assessing the equivalence of inhaled products , 1998 .

[2]  P. Munkholm.  Crohn's disease--occurrence, course and prognosis. An epidemiologic cohort-study. , 1997, Danish medical bulletin.

[3]  W. Kruis,et al.  COMPARISON OF AN AZOBOUND AMINO SALICYLATE (OLSALAZINE) VS. A COATED AMINOSALICYLATE (MESALAMINE) FOR ACTIVE ULCERATIVE COLITIS: 525 , 1997 .

[4]  P. Poitras,et al.  Release of 5‐ASA from Pentasa in patients with Crohn's disease of the small intestine , 1995, Alimentary pharmacology & therapeutics.

[5]  U. Klotz,et al.  Delivery and fate of oral mesalamine microgranules within the human small intestine. , 1995, Gastroenterology.

[6]  R. Gurny,et al.  In vivo evaluation of dosage forms: application of gamma scintigraphy to non-enteral routes of administration. , 1994, Journal of drug targeting.

[7]  J. Teare,et al.  The mode of action of the aminosalicylates in inflammatory bowel disease , 1993 .

[8]  S. Hanauer,et al.  Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.

[9]  I. Wilding,et al.  Localization of Drug Release Sites from an Oral Sustained‐Release Formulation of 5‐ASA (Pentasa®) in the Gastrointestinal Tract Using Gamma Scintigraphy , 1993, Journal of clinical pharmacology.

[10]  S. Hanauer,et al.  Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. , 1993, Gastroenterology.

[11]  I. Wilding,et al.  Colonic transit of different sized tablets in healthy subjects , 1993 .

[12]  R. Modigliani,et al.  Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) , 1993, Gastroenterology.

[13]  R. N. Brogden,et al.  Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. , 1989, Drugs.

[14]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[15]  J. Hardy,et al.  Evaluation of an enteric‐coated delayed‐release 5‐aminosalicylic acid tablet in patients with inflammatory bowel disease , 1987, Alimentary pharmacology & therapeutics.

[16]  M. Marvola,et al.  Gastrointestinal Transit and Concomitant Absorption of Verapamil from a Single-Unit Sustained-Release Tablet , 1987 .

[17]  S. Davis,et al.  Alimentary tract andpancreas Transit ofpharmaceutical dosage forms through the , 1986 .

[18]  Hardy Jg,et al.  Validity of the geometric mean correction in the quantification of whole bowel transit. , 1985 .

[19]  A. Perkins,et al.  Validity of the geometric mean correction in the quantification of whole bowel transit , 1985, Nuclear medicine communications.

[20]  S. Hansen,et al.  5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. , 1982, Gastroenterology.

[21]  S. Truelove,et al.  AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE , 1977, The Lancet.

[22]  H. Schröder,et al.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man , 1972, Clinical pharmacology and therapeutics.

[23]  J. N. Hunt,et al.  The influence of volume on gastric emptying , 1954, The Journal of physiology.